BEST UNLIMITED TURBO SHORT CERTIFICATE - BRISTOL-MYERS SQUIBB BEST UNLIMITED TURBO SHORT CERTIFICATE - BRISTOL-MYERS SQUIBB Share Price
Certificat
U663S
DE000SU675M9
| Market Closed - Euronext Paris 17:30:01 15/05/2024 BST | ||
| 2.775 EUR | -1.07% |
|
| Current month | -2.46% | ||
| 1 month | +33.73% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 15/05/24 | 2.775 | -1.07% |
| 14/05/24 | 2.805 | +2.94% |
| 13/05/24 | 2.725 | -2.85% |
| 10/05/24 | 2.805 | -5.40% |
| 09/05/24 | 2.965 | -1.00% |
Real-time Euronext Paris
Last update May 15, 2024 at 05:30 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| U663S | |
| ISIN | DE000SU675M9 |
| Date issued | 22/01/2024 |
| Strike | 59.58 $ |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 1.88 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.065 € |
|---|---|
| Lowest since issue | 1.01 € |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
25
Last Close Price
44.71
USD
Average target price
53.19
USD
Spread / Average Target
+18.98%
- Stock Market
- Certificates
- U663S Certificat
